|Mr. Jeffrey B. Kindler||Exec. Chairman||N/A||N/A||1956|
|Mr. Stephen L. Holcombe||Pres & CEO||682.15k||N/A||1957|
|Mr. Rudy C. Howard CPA, B.A., CPA||Exec. VP & CFO||484.55k||N/A||1958|
|Dr. Larry Douglas Altstiel||Exec. VP & Chief Medical Officer||582.2k||N/A||1950|
|Dr. Carmen Valcarce Ph.D.||Chief Scientific Officer & Exec. VP||N/A||N/A||N/A|
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease. Its drug candidates also include TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase 2b clinical trials for the treatment of type 2 diabetes, as well as initiated Phase 1b/2 clinical trials for the treatment of type 1 diabetes; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. vTv Therapeutics Inc. has a license and research agreement with Calithera Biosciences, Inc. to develop and commercialize its hexokinase II inhibitors for therapeutic, prophylactic, preventative, or diagnostic use. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of vTv Therapeutics Holdings LLC.
vTv Therapeutics Inc.’s ISS Governance QualityScore as of April 1, 2018 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 4; Compensation: 8.